Serum osteoprotegerin and renal function in the general population: the Tromsø Study
- PMID: 28638603
- PMCID: PMC5469572
- DOI: 10.1093/ckj/sfw095
Serum osteoprotegerin and renal function in the general population: the Tromsø Study
Abstract
Background: Serum osteoprotegerin (OPG) is elevated in patients with chronic kidney disease (CKD) and increases with decreasing renal function. However, there are limited data regarding the association between OPG and renal function in the general population. The aim of the present study was to explore the relation between serum OPG and renal function in subjects recruited from the general population.
Methods: We conducted a cross-sectional study with 6689 participants recruited from the general population in Tromsø, Norway. Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equations. OPG was modelled both as a continuous and categorical variable. General linear models and linear regression with adjustment for possible confounders were used to study the association between OPG and eGFR. Analyses were stratified by the median age, as serum OPG and age displayed a significant interaction on eGFR.
Results: In participants ≤62.2 years with normal renal function (eGFR ≥90 mL/min/1.73 m2) eGFR increased by 0.35 mL/min/1.73 m2 (95% CI 0.13-0.56) per 1 standard deviation (SD) increase in serum OPG after multiple adjustment. In participants older than the median age with impaired renal function (eGFR <90 mL/min/1.73 m2), eGFR decreased by 1.54 (95% CI -2.06 to -1.01) per 1 SD increase in serum OPG.
Conclusions: OPG was associated with an increased eGFR in younger subjects with normal renal function and with a decreased eGFR in older subjects with reduced renal function. Our findings imply that the association between OPG and eGFR varies with age and renal function.
Keywords: estimated glomerular filtration rate; general population; osteoprotegerin; renal function.
Figures


Similar articles
-
Elevated osteoprotegerin predicts declining renal function in elderly women: a 10-year prospective cohort study.Am J Nephrol. 2014;39(1):66-74. doi: 10.1159/000357787. Epub 2014 Jan 21. Am J Nephrol. 2014. PMID: 24457210
-
Elevated Circulating Osteoprotegerin and Renal Dysfunction Predict 15-Year Cardiovascular and All-Cause Mortality: A Prospective Study of Elderly Women.PLoS One. 2015 Jul 29;10(7):e0134266. doi: 10.1371/journal.pone.0134266. eCollection 2015. PLoS One. 2015. PMID: 26222774 Free PMC article. Clinical Trial.
-
Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications.Nephrol Dial Transplant. 2015 Aug;30(8):1345-56. doi: 10.1093/ndt/gfv081. Epub 2015 Apr 7. Nephrol Dial Transplant. 2015. PMID: 25854266 Review.
-
Serum osteoprotegerin and future risk of cancer and cancer-related mortality in the general population: the Tromsø study.Eur J Epidemiol. 2015 Mar;30(3):219-30. doi: 10.1007/s10654-014-9975-3. Epub 2014 Dec 2. Eur J Epidemiol. 2015. PMID: 25446307
-
Longitudinal assessment of estimated glomerular filtration rate in apparently healthy adults: a post hoc analysis from the JUPITER study (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).Clin Ther. 2011 Jun;33(6):717-25. doi: 10.1016/j.clinthera.2011.05.004. Clin Ther. 2011. PMID: 21704236 Clinical Trial.
Cited by
-
Osteoprotegerin and Inflammation in Incident Peritoneal Dialysis Patients.J Clin Med. 2024 Apr 18;13(8):2345. doi: 10.3390/jcm13082345. J Clin Med. 2024. PMID: 38673616 Free PMC article.
-
Circulating Osteoprotegerin in Chronic Kidney Disease and All-Cause Mortality.Int J Gen Med. 2021 Jun 9;14:2413-2420. doi: 10.2147/IJGM.S302251. eCollection 2021. Int J Gen Med. 2021. PMID: 34135625 Free PMC article.
-
Associations of Proteomics With Hypertension and Systolic Blood Pressure: KORA S4/F4/FF4 and KORA Age1/Age2 Cohort Studies.Hypertension. 2024 May;81(5):1156-1166. doi: 10.1161/HYPERTENSIONAHA.123.22614. Epub 2024 Mar 6. Hypertension. 2024. PMID: 38445514 Free PMC article.
-
Osteoprotegerin is a marker of cardiovascular mortality in patients with chronic kidney disease stages 3-5.Sci Rep. 2021 Jan 28;11(1):2473. doi: 10.1038/s41598-021-82072-z. Sci Rep. 2021. PMID: 33510348 Free PMC article. Clinical Trial.
-
The Correlation of Serum Osteoprotegerin with Non-Traditional Cardiovascular Risk Factors and Arterial Stiffness in Patients with Pre-Dialysis Chronic Kidney Disease: Results from the KNOW-CKD Study.J Korean Med Sci. 2018 Dec 11;33(53):e322. doi: 10.3346/jkms.2018.33.e322. eCollection 2018 Dec 31. J Korean Med Sci. 2018. PMID: 30595681 Free PMC article.
References
-
- Hofbauer LC, Schoppet M. Osteoprotegerin: a link between osteoporosis and arterial calcification? Lancet 2001; 358: 257–259 - PubMed
-
- Simonet WS, Lacey DL, Dunstan CR et al. . Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309–319 - PubMed
-
- Schoppet M, Sattler AM, Schaefer JR et al. . Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003; 88: 1024–1028 - PubMed
-
- Jono S, Ikari Y, Shioi A et al. . Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002; 106: 1192–1194 - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous